Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families
|
|
- Aileen Greene
- 5 years ago
- Views:
Transcription
1 Breast Cancer Res Treat (2010) 124: DOI /s BRIEF REPORT Large BRCA1 and BRCA2 genomic rearrangements in Malaysian high risk breast-ovarian cancer families Peter Kang Shivaani Mariapun Sze Yee Phuah Linda Shushan Lim Jianjun Liu Sook-Yee Yoon Meow Keong Thong Nur Aishah Mohd Taib Cheng Har Yip Soo-Hwang Teo Received: 21 June 2010 / Accepted: 23 June 2010 / Published online: 9 July 2010 Ó Springer Science+Business Media, LLC Abstract Early studies of genetic predisposition due to the BRCA1 and BRCA2 genes have focused largely on sequence alterations, but it has now emerged that 4 28% of inherited mutations in the BRCA genes may be due to large genomic rearrangements of these genes. However, to date, there have been relatively few studies of large genomic rearrangements in Asian populations. We have conducted a full sequencing and large genomic rearrangement analysis (using Multiplex Ligation-dependent Probe Amplification, MLPA) of 324 breast cancer patients who were selected from a multi-ethnic hospital-based cohort on the basis of age of onset of breast cancer and/or family history. Three unrelated individuals were found to have large genomic rearrangements: 2 in BRCA1 and 1 in BRCA2, which P. Kang S. Mariapun S. Y. Phuah S.-Y. Yoon S.-H. Teo (&) Cancer Research Initiatives Foundation, Sime Darby Medical Centre, 2nd Floor, Outpatient Centre, 1 Jalan SS12/1A, Subang Jaya 47500, Selangor, Malaysia soohwang.teo@carif.com.my L. S. Lim J. Liu Human Genetics Division, Genome Institute of Singapore, Agency for Science Technology & Research (A*STAR), Singapore, Singapore J. Liu Centre for Molecular Epidemiology, Yong Loo Lin School of Medicine, National University of Singapore, Singapore, Singapore M. K. Thong Department of Paediatrics, University Malaya Medical Centre, Kuala Lumpur, Malaysia N. A. Mohd Taib C. H. Yip S.-H. Teo Department of Surgery, University Malaya Medical Centre, Kuala Lumpur, Malaysia accounts for 2/24 (8%) of the total mutations detected in BRCA1 and 1/23 (4%) of the mutations in BRCA2 detected in this cohort. Notably, the family history of the individuals with these mutations is largely unremarkable suggesting that family history alone is a poor predictor of mutation status in Asian families. In conclusion, this study in a multi-ethnic (Malay, Chinese, Indian) cohort suggests that large genomic rearrangements are present at a low frequency but should nonetheless be included in the routine testing for BRCA1 and BRCA2. Keywords Breast cancer BRCA1 BRCA2 Rearrangements Germline Introduction Genetic testing to identify deleterious BRCA1 and BRCA2 mutations in families with history of breast or ovarian cancer has become an integral part of clinical practice in many countries. Although early tests have focused primarily on sequence alterations, more recently, numerous studies conducted primarily in Caucasian populations have shown that 4 28% of mutations in the BRCA genes may be due to large genomic rearrangements [1]. At least 81 different BRCA1 genomic rearrangements and 17 BRCA2 genomic rearrangements have been reported to date ([2] and references therein). However, there have been relatively few reports of such large genomic rearrangements from Asia, with only seven reports involving a total of 649 patients from Hong Kong, Singapore, Korea, Japan and Malaysia [3 9]. This is in part because there have been relatively few studies involving comprehensive analysis of BRCA1 and BRCA2 in Asia, and to date, few Asian countries have had the resources and
2 580 Breast Cancer Res Treat (2010) 124: finances for breast cancer genetic counseling and genetic testing services. Moreover, there have been major challenges in identifying at risk individuals because unlike Caucasian populations where multiplex families and extensive family history are available, the majority of Asian families do not fulfil the typical high risk profile described in other populations because of the lack of accurate reporting of family history of cancer, complex family dynamics and the lower age-standardised rate of breast cancer in Asia [10, 11]. The aim of our study was to assess the prevalence of large genomic rearrangements in BRCA genes in a breast cancer cohort previously tested negative for BRCA mutations using DNA sequencing. Materials and methods Breast cancer cohort The recruitment of Malaysian families with a high risk of breast or ovarian cancer started in 2003 at the University Malaya Medical Centre in Kuala Lumpur [10]. Patients with breast cancer were first approached by clinicians responsible for their care to see if they would participate in a research study to determine the genetic factors which increase the risk of breast cancer in Malaysia. Thereafter, individuals interested in the project were approached by a member of the research team who explained to them the nature and objectives of the research project. A total of 1,077 index cases were referred to our study between January 2003 and December Index cases signed a consent form and a blood sample was taken. A family history was recorded and the pedigree analysed. Where possible, pathology reports were requested to confirm all diagnoses of breast and ovarian cancers in the index case. The study was approved by the ethics committee of University Malaya Medical Centre. Inclusion criteria for analysis of BRCA1 and BRCA2 Breast cancer patients were included for analysis of BRCA1 and BRCA2 if they were considered high-risk by the following criteria: (a) early-onset breast cancer (B40 years) and 1 or more additional cases of breast cancer in first- or second-degree relatives; (b) breast cancer (C40 years) and two or more additional cases of breast cancer in first- or second-degree relatives; (c) bilateral breast cancer (\50 years old); or (d) breast cancer and a personal or family history of breast and ovarian cancer. In addition, approximately 50% of patients who were considered of medium risk were included for analysis. These included patients with only early-onset breast cancer (B40 years) but no significant family history [12] or breast cancer (C40 years) and one additional case of breast cancer in a first- or second-degree relative. Individuals were categorised based on self-reported race or ethnicity [10]. Of the 1,077 index cases, 324 were analysed for mutations in the BRCA1 and BRCA2 genes. Mutation detection Blood from index cases was separated into two 10 ml EDTA-tubes and DNA was extracted using standard methods. Samples were tested for mutations in the BRCA1 and BRCA2 genes using direct DNA sequencing as previously described. Those samples which tested wild-type (mutation negative) were subsequently analysed by multiplex ligation-dependent probe amplification (MLPA) using kit P002B/P087 (MRC-Holland, Amsterdam) which includes probes for each of the 24 exons of BRCA1 and kit P045, which includes probes for the 27 exons of BRCA2 and for exon 9 of CHEK2. Confirmation tests were performed on a second blood sample. Naming and interpretation of sequence analysis (BRCA1 gdna sequence: accession no. L78833; BRCA2 gdna sequence: accession no. AY436640) were performed as previously described [4] and all patients were classified as having a deleterious mutation if the BRCA1 or BRCA2 protein terminated prematurely at least 10 or 110 amino acids, respectively, from the C terminus. Identification of genomic breakpoints Putative deletions were evaluated in genomic DNA by long-range PCR. PCR primers were located in introns flanking the rearrangement and PCR products of abnormal size were sequenced in both directions. Detection of BRCA1 exon 1 14 deletion in BRC 776 by Illumina SNP array DNA samples were analyzed on the Illumina Human 1M- Duo DNA Analysis BeadChip (Illumina Inc.) according to manufacturer s protocol. Raw signals were processed using the GenomeStudio TM Data Analysis Software s Genotyping Module (Illumina Inc.) to give Log R Ratio (LRR) and B Allele Frequency (BAF) readings. Large deletions in genomic DNA were called using the QuantiSNP v1.1 algorithm [13] on exported Illumina LRR and BAF values for each sample. The following stringent QC criteria were applied to ensure high-quality calls: (1) LRR standard
3 Breast Cancer Res Treat (2010) 124: Table 1 Characteristics of families with negative BRCA1 and BRCA2 (n = 280) Characteristics No. (%) Cancer type Female breast, age at index diagnosis, years B C Breast or ovarian cancers in family (1 and 2 only) Female breast Female ovary 7 3 Both 1 Neither Manchester score B C Ancestry Malay Chinese Indian Others 4 1 A total of 324 breast cancer patients were analysed for mutations in BRCA1 and BRCA2 by DNA sequencing and multiple ligation dependent probe amplification (MLPA) analysis. Table 1 shows the distribution of patients according to their age at diagnosis, family history of breast and ovarian cancer in first- and second-degree relatives, Manchester score and self-declared ethnicity. Notably, the 135 individuals with no family history of breast and ovarian cancer were included in the study because they had either early age of onset of breast cancer (B40 years of age: 88 individuals; years of age: 35 individuals), bilateral breast cancer (28 individuals), both breast and ovarian cancer (4 individuals) or family history of prostate cancer in the third degree (6 individuals) deviation \ 0.2; (2) Minimum no. of SNPs [ 10; and (3) Log Bayes Factor [ 30. This analysis reported regions with genomic copy number deviating from 2, and provided details on chromosomal coordinates, number and identity of implicated SNPs, and chromosomal copy number (0 or 1, for homozygous or heterozygous deletions, respectively) for each region. Results Mutation testing outcome A total of 2,407 patients with breast cancer were treated at the University Malaya Medical Centre between January 2003 and December 2009, of which 1,077 individuals with breast cancer were recruited to the present study. We conducted full sequence analysis of the BRCA1 and BRCA2 genes in 324 high- and medium-risk women (see Materials and methods and Table 1). DNA sequencing analysis led to the discovery of 37 distinct deleterious mutations in 44 individuals (BRCA1 185 delag and BRCA2 490 delct were found in 3 individuals each; and BRCA1 589 delct, BRCA G[T and BRCA C[G were found in 2 individuals each). Detection of large genomic rearrangements using multiplex ligation PCR amplification (MLPA) revealed two genomic rearrangements in BRCA1 and one in BRCA2. Large genomic rearrangements therefore account for 2/24 (8%) of the total mutations detected in BRCA1 and 1/23 (4%) of the mutations in BRCA2 detected in this cohort (Table 2). BRCA1 exon deletion Patient BRC748 is an Indian breast cancer patient who developed breast cancer at the age of 29, but has no family history of breast and ovarian cancer (Fig. 1a). Her rearrangement involved the deletion of exons of BRCA1 (Table 2). Using primers located in introns 12 and 15, mutant PCR products were amplified from the genomic DNA of BRC748 and sequenced using a series of internal primers (Table 3; [4]). The 5 0 breakpoint of the 9,400 base pair deletion occurred 794 bp upstream of exon 13 in intron 12, and the 3 0 breakpoint occurred 360 bp downstream of exon 15 in intron 15. Sequence analysis indicated that the 5 0 and 3 0 breakpoint of the deletion occurred within two AluSX repeats oriented in the same forward direction, at locations 45,276 45,572 and 54,676 54,964, respectively, and the site of the crossover even was shown to lie within a 21 bp sequence. In addition, a mutation-specific PCR assay was used for determining the prevalence of this BRCA1 rearrangement Table 2 Inherited genomic rearrangements in BRCA1 and BRCA2 Patient Mutation Size, bp Type of sequence at breakpoint Ancestries of families with mutation 5 0 site 3 0 site BRC748 BRCA1 exon 13_15 del 9,400 AluSX AluSX Indian BRC776 BRCA1 exon 1_14 del *78,500 ND ND Chinese BRC888 BRCA2 exon 14_16 del 6,859 AGACTG AGACTG Indian
4 582 Breast Cancer Res Treat (2010) 124: Table 3 Primer sequences used for sequencing analysis of BRCA1 and BRCA2 rearrangements Primer Nucleotide sequence Nucleotide position a BRCA1 exon deletion analysis B1int12F GCACACTCTTCTTTGAAATGGA ,944 44,481 B1int15R TTTTTGAGATGGAGTCTTGCTC ,943 54,964 B1int15R2 b 5 0 -CCTTTGGACTCTTGTCTAACAG ,026 55,047 BRCA2 exon deletion analysis B2int13F CACCTGATTGTGGAATTGTTG ,880 37,900 B2int13F GGGACAGAGGGAAACAAAAA ,378 38,397 B2int16R5b 5 0 -TTAAAAATCGCATCTCCTTGC ,812 45,832 a Nucleotide positions are numbered according to BRCA1 and BRCA2 genomic sequences, L78833 and AY436640, respectively b Primer sequence from Lim et al. [4] (a) Throat ca, ~60 Breast ca, Brain tumour, 1 Uterine ca, 42 Leukaemia, 4 (b) Ovarian/cervical/uterine ca, ~50 Colon ca, 75 Kidney ca, ~50 Lung ca, ~50 Lung ca, ~ Breast ca, 57 Ovarian ca, ~60 Ovarian ca, ~60 4 Ovarian ca, ~40 Colon ca, ~ (c) Breast ca, ~ Breast ca, 33 Breast ca, 47 Gastric ca, 43 CRC & Brain ca, Fig. 1 Pedigree of families with genomic rearrangements in BRCA1 and BRCA2, indicating the positions of affected individuals (open circle females; open square males). Index patients are indicated with an arrow. Patients who tested positive or negative for BRCA mutations are indicated with? or -, respectively. a BRC 748, b BRC 776, c BRC 888
5 Breast Cancer Res Treat (2010) 124: mutation in 121 Indian breast cancer patients and no other individuals were found to have this mutation. BRCA1 exon 1 14 deletion In patient BRC776, a Chinese breast cancer patient who developed breast cancer at the age of 57 and who had family history of ovarian and other cancers (Fig. 1b), the rearrangement involved deletion of exons 1 14 of BRCA1. Using the Illumina SNP chip, we found that there was heterozygote loss of rs (located at 38,485,428 on chromosome 17) and intervening regions to rs (located at 38,564,021) showing that there is a loss of approximately 78,500 bp of sequence from the promoter region of BRCA1 to exon 14. BRCA2 exon deletion In patient BRC888, an Indian breast cancer patient who developed breast cancer at the age of 33 and who had family history of breast cancer (Fig. 1c), the rearrangement involved deletion of exons of BRCA2. In order to delineate the breakpoint, a series of PCR amplifications were performed using different combinations of forward and reverse primers located in introns 13 and 16. The 5 0 breakpoint of the 6,859 base pair deletion occurred 1,962 bp upstream of exon 14, and the 3 0 breakpoint occurred 1,827 bp downstream of exon 16 in intron 16 (Table 3). Sequence analysis indicated that the 5 0 and 3 0 breakpoint of the deletion occurred within 38,654 38,659 and 45,513 45,518, respectively. Notably, the breakpoint did not occur in an Alu or LINE sequence, but appeared to take place across a region with microhomology. In addition, a mutation-specific PCR assay was used for determining the prevalence of this BRCA2 rearrangement mutation in 121 Indian breast cancer patients and no other individuals were found to have this mutation. Discussion This study provides important data on the prevalence and spectrum of large genome rearrangements in the BRCA1 and BRCA2 genes in the multi-ethnic population of Malaysia. Our results indicate that 14% (47/324) of those from medium to high risk families in Malaysia carry cancer predisposing genomic deletions in BRCA1 or BRCA2 and that large genomic rearrangements constitute 8% (2/24) and 4% (1/23) of the total BRCA1 and BRCA2 mutations, respectively, in this cohort. Our results are consistent with previous studies in various European populations ([14] and references therein; [15 28]) and in Singapore ([4] and references therein) where large genomic rearrangements constitute 8 and 4% of the total BRCA1 and BRCA2 mutations, respectively. We would therefore suggest that large genomic rearrangements, though present at a low frequency, should nonetheless be included in the routine testing for BRCA1 and BRCA2. Genomic rearrangements were found in 3 of the mutation negative families and 1% (3/324) of the medium- and high-risk families. Of the 3 patients who were shown to have large genomic rearrangements in the BRCA genes, their Manchester scores were 11, 14 and 24. Two of these scores are typically only medium risk and further highlight the urgent need for more robust risk prediction models for Asians in order to identify individuals who have inherited predisposition to breast cancer. In addition, it is notable that two studies suggest BRCA2 genomic rearrangements should only be screened in presence of male breast cancer [18, 29], but the family with the BRCA2 large genomic rearrangement did not have any reported male breast cancer in the family. Acknowledgements We thank participants and their families for taking part in this study and Lee Sheau Yee, Eswary Thirthagiri and Daphne Lee for assistance with DNA preparation, pathology data and helpful discussions. This study was funded by research grants from the Malaysian Ministry of Science, Technology and Innovation, University Malaya and Cancer Research Initiatives Foundation. References 1. Mazoyer S (2005) Genomic rearrangements in the BRCA1 and BRCA2 genes. Hum Mutat 25(5): Sluiter MD, van Rensburg EJ (2010) Large genomic rearrangements of the BRCA1 and BRCA2 genes: review of the literature and report of a novel BRCA1 mutation. Breast Cancer Res Treat. doi: /s z 3. Kwong A et al (2009) A BRCA2 founder mutation and seven novel deleterious BRCA mutations in southern Chinese women with breast and ovarian cancer. Breast Cancer Res Treat 117(3): Lim YK et al (2007) Identification of novel BRCA large genomic rearrangements in Singapore Asian breast and ovarian patients with cancer. Clin Genet 71(4): Ang P et al (2007) BRCA1 and BRCA2 mutations in an Asian clinic-based population detected using a comprehensive strategy. Cancer Epidemiol Biomarkers Prev 16(11): Yap KP et al (2006) Detection of a novel Alu-mediated BRCA1 exon 13 duplication in Chinese breast cancer patients and implications for genetic testing. Clin Genet 70(1): Seong MW et al (2009) Low contribution of BRCA1/2 genomic rearrangement to high-risk breast cancer in the Korean population. Fam Cancer 8(4): Miki Y et al (1996) Mutation analysis in the BRCA2 gene in primary breast cancers. Nat Genet 13(2): Sharifah NA, et al (2010) Identification of novel large genomic rearrangements at the BRCA1 locus in Malaysian women with breast cancer. Cancer Epidemiol. doi: /j.canep Thirthagiri E et al (2008) Evaluation of BRCA1 and BRCA2 mutations and risk-prediction models in a typical Asian country
6 584 Breast Cancer Res Treat (2010) 124: (Malaysia) with a relatively low incidence of breast cancer. Breast Cancer Res 10(4):R Rao NY et al (2009) Evaluating the performance of models for predicting the BRCA germline mutations in Han Chinese familial breast cancer patients. Breast Cancer Res Treat 116(3): Toh GT et al (2008) BRCA1 and BRCA2 germline mutations in Malaysian women with early-onset breast cancer without a family history. PLoS One 3(4):e Colella S et al (2007) QuantiSNP: an objective Bayes Hidden Markov Model to detect and accurately map copy number variation using SNP genotyping data. Nucleic Acids Res 35(6): Walsh T et al (2006) Spectrum of mutations in BRCA1, BRCA2, CHEK2, and TP53 in families at high risk of breast cancer. JAMA 295(12): Ratajska M et al (2008) BRCA1 and BRCA2 point mutations and large rearrangements in breast and ovarian cancer families in Northern Poland. Oncol Rep 19(1): Hansen TO et al (2009) Large BRCA1 and BRCA2 genomic rearrangements in Danish high risk breast-ovarian cancer families. Breast Cancer Res Treat 115(2): Pylkas K et al (2008) Analysis of large deletions in BRCA1, BRCA2 and PALB2 genes in Finnish breast and ovarian cancer families. BMC Cancer 8: Engert S et al (2008) MLPA screening in the BRCA1 gene from 1,506 German hereditary breast cancer cases: novel deletions, frequent involvement of exon 17, and occurrence in single earlyonset cases. Hum Mutat 29(7): Miramar MD et al (2008) Genetic analysis of BRCA1 and BRCA2 in breast/ovarian cancer families from Aragon (Spain): two novel truncating mutations and a large genomic deletion in BRCA1. Breast Cancer Res Treat 112(2): Purnomosari D et al (2007) BRCA1 and BRCA2 germline mutation analysis in the Indonesian population. Breast Cancer Res Treat 106(2): Veschi S et al (2007) High prevalence of BRCA1 deletions in BRCAPRO-positive patients with high carrier probability. Ann Oncol 18(6):vi86 vi Vasickova P et al (2007) High occurrence of BRCA1 intragenic rearrangements in hereditary breast and ovarian cancer syndrome in the Czech Republic. BMC Med Genet 8: Gutierrez-Enriquez S et al (2007) Screening for large rearrangements of the BRCA2 gene in Spanish families with breast/ ovarian cancer. Breast Cancer Res Treat 103(1): Palanca Suela S et al (2008) Identification of a novel BRCA1 large genomic rearrangement in a Spanish breast/ovarian cancer family. Breast Cancer Res Treat 112(1): Weitzel JN et al (2007) Evidence for common ancestral origin of a recurring BRCA1 genomic rearrangement identified in high-risk Hispanic families. Cancer Epidemiol Biomarkers Prev 16(8): Casilli F et al (2006) The contribution of germline rearrangements to the spectrum of BRCA2 mutations. J Med Genet 43(9):e Buffone A et al (2007) Prevalence of BRCA1 and BRCA2 genomic rearrangements in a cohort of consecutive Italian breast and/or ovarian cancer families. Breast Cancer Res Treat 106(2): Armaou S et al (2007) Novel genomic rearrangements in the BRCA1 gene detected in Greek breast/ovarian cancer patients. Eur J Cancer 43(2): Tournier I et al (2004) Significant contribution of germline BRCA2 rearrangements in male breast cancer families. Cancer Res 64(22):
Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country
DOI 10.1007/s00268-009-0146-8 Clinical and Pathologic Differences Between BRCA1-, BRCA2-, and Non-BRCA-Associated Breast Cancers in a Multiracial Developing Country Cheng-Har Yip Æ N. A. Taib Æ W. Y. Choo
More informationMRC-Holland MLPA. Description version 18; 09 September 2015
SALSA MLPA probemix P090-A4 BRCA2 Lot A4-0715, A4-0714, A4-0314, A4-0813, A4-0712: Compared to lot A3-0710, the 88 and 96 nt control fragments have been replaced (QDX2). This product is identical to the
More informationProduct Description SALSA MLPA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.
Product Description SALSA probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. As compared to version C2, 12 extra BRCA1 probes and 3 probes for exon 24 have been included, and
More informationNew: P077 BRCA2. This new probemix can be used to confirm results obtained with P045 BRCA2 probemix.
SALSA MLPA KIT P045-B2 BRCA2/CHEK2 Lot 0410, 0609. As compared to version B1, four reference probes have been replaced and extra control fragments at 100 and 105 nt (X/Y specific) have been included. New:
More informationThe impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice
The impact of hereditary breast and ovarian cancer (HBOC) syndrome testing on patient management and your practice Use BRACAnalysis as a guide in your medical and surgical management BRACAnalysis testing
More informationPanel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research
Panel Testing and SNP Testing (Polygenic Risk Score) in Asian Women Soo Teo PhD FASc Head of Breast Cancer Research Programme Cancer Research Malaysia E mail: soohwang.teo@cancerresearch.my How much of
More informationcohort of ovarian cancer patients
Accepted Manuscript Evaluation of germline BRCA1 and BRCA2 mutations in a multi-ethnic Asian cohort of ovarian cancer patients Hanis Nazihah Hasmad, Kah Nyin Lai, Wei Xiong Wen, Daniel Jonathan Park, Tú
More informationMedical Policy Manual. Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer. Date of Origin: January 27, 2011
Medical Policy Manual Topic: Genetic Testing for Hereditary Breast and/or Ovarian Cancer Date of Origin: January 27, 2011 Section: Genetic Testing Last Reviewed Date: July 2014 Policy No: 02 Effective
More informationMRC-Holland MLPA. Description version 29;
SALSA MLPA KIT P003-B1 MLH1/MSH2 Lot 1209, 0109. As compared to the previous lots 0307 and 1006, one MLH1 probe (exon 19) and four MSH2 probes have been replaced. In addition, one extra MSH2 exon 1 probe,
More informationHaplotype analysis reveals that the recurrent BRCA1 deletion of exons 23 and 24 is a Greek founder mutation
Clin Genet 2017: 91: 482 487 Printed in Singapore. All rights reserved Short Report 2016 John Wiley & Sons A/S. Published by John Wiley & Sons Ltd CLINICAL GENETICS doi: 10.1111/cge.12824 Haplotype analysis
More informationGENETIC VARIATION OF THE BRCA1 AND BRCA2 GENES IN MACEDONIAN PATIENTS
BJMG Supplement 15 (2012) 81-85 10.2478/v10034 012 0025 8 Proceedings of the MACPROGEN Final Conference held at Ohrid, Republic of Macedonia, March 29-April 1 2012 GENETIC VARIATION OF THE BRCA1 AND BRCA2
More informationAbstract. Optimization strategy of Copy Number Variant calling using Multiplicom solutions APPLICATION NOTE. Introduction
Optimization strategy of Copy Number Variant calling using Multiplicom solutions Michael Vyverman, PhD; Laura Standaert, PhD and Wouter Bossuyt, PhD Abstract Copy number variations (CNVs) represent a significant
More informationMRC-Holland MLPA. Related SALSA MLPA probemixes P190 CHEK2: Breast cancer susceptibility, genes included: CHEK2, ATM, PTEN, TP53.
SALSA MLPA probemix P056-C1 TP53 Lot C1-0215 & lot C1-0214. As compared to version B1 (lot B1-1011) most of the reference and flanking probes have been replaced and several have been added. Furthermore,
More informationProduct Description SALSA MLPA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.
Product Description SALSA probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19
More informationThe Genetics of Breast and Ovarian Cancer Prof. Piri L. Welcsh
The Genetics of Breast Piri L. Welcsh, PhD Research Assistant Professor University of Washington School of Medicine Division of Medical Genetics 1 Genetics of cancer All cancers arise from genetic and
More informationDOES THE BRCAX GENE EXIST? FUTURE OUTLOOK
CHAPTER 6 DOES THE BRCAX GENE EXIST? FUTURE OUTLOOK Genetic research aimed at the identification of new breast cancer susceptibility genes is at an interesting crossroad. On the one hand, the existence
More informationSupplementary Text. Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry
Supplementary Text Novel variants in NUDT15 and thiopurine intolerance in children with acute lymphoblastic leukemia from diverse ancestry Takaya Moriyama a, Yung-Li Yang b, Rina Nishii a, c, Hany Ariffin
More informationCorporate Medical Policy
Corporate Medical Policy Moderate Penetrance Variants Associated with Breast Cancer in File Name: Origination: Last CAP Review: Next CAP Review: Last Review: moderate_penetrance_variants_associated_with_breast_cancer_
More informationIdentification of patients suggestive of hereditary breast and ovarian cancer syndrome that warrants further professional evaluation.
Allina Breast Program Committee Consensus Guidelines These guidelines apply to clinical interventions that have well-documented outcomes, but whose outcomes are not clearly desirable to all patients Identification
More informationHigh prevalence of BRCA1 deletions in BRCAPROpositive patients with high carrier probability
18 (Supplement 6): vi86 vi92, 2007 doi:10.1093/annonc/mdm233 High prevalence of BRCA1 deletions in BRCAPROpositive patients with high carrier probability S. Veschi 2,3, G. Aceto 2,3, A. P. Scioletti 2,4,
More informationGermline Testing for Hereditary Cancer with Multigene Panel
Germline Testing for Hereditary Cancer with Multigene Panel Po-Han Lin, MD Department of Medical Genetics National Taiwan University Hospital 2017-04-20 Disclosure No relevant financial relationships with
More informationHST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007
MIT OpenCourseWare http://ocw.mit.edu HST.161 Molecular Biology and Genetics in Modern Medicine Fall 2007 For information about citing these materials or our Terms of Use, visit: http://ocw.mit.edu/terms.
More informationProduct Description SALSA MLPA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P045-C1 BRCA2/CHEK2 To be used with the MLPA General Protocol. Version C1. As compared to version B3, the probes for the BRCA2 upstream region and exons 8, 11, 12, 19
More informationCANCER GENETICS PROVIDER SURVEY
Dear Participant, Previously you agreed to participate in an evaluation of an education program we developed for primary care providers on the topic of cancer genetics. This is an IRB-approved, CDCfunded
More informationMRC-Holland MLPA. Description version 29; 31 July 2015
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0114. As compared to the previous B2 version (lot 0813 and 0912), 11 target probes are replaced or added, and 10 new reference probes are included. P082
More informationUsing the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep
Using the Bravo Liquid-Handling System for Next Generation Sequencing Sample Prep Tom Walsh, PhD Division of Medical Genetics University of Washington Next generation sequencing Sanger sequencing gold
More informationBRCA 1/2. Breast cancer testing THINK ABOUT TOMORROW, TODAY
BRCA 1/2 Breast cancer testing THINK ABOUT TOMORROW, TODAY 5 10% of patients with breast and/or ovarian cancer have a hereditary form1. For any individual carrying a mutation in BRCA1 or BRCA2, the lifetime
More informationIdentification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome
Identification of a novel duplication mutation in the VHL gene in a large Chinese family with Von Hippel-Lindau (VHL) syndrome L.H. Cao 1, B.H. Kuang 2, C. Chen 1, C. Hu 2, Z. Sun 1, H. Chen 2, S.S. Wang
More informationGENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER SYNDROME BRCA1 BRCA2
SYNDROME BRCA1 BRCA2 Non-Discrimination Statement and Multi-Language Interpreter Services information are located at the end of this document. Coverage for services, procedures, medical devices and drugs
More informationRisk-reducing Surgery in BRCA mutation carriers
Risk-reducing Surgery in BRCA mutation carriers Daerim St. Mary s Hospital Department of Surgery, Breast Care Center Hereditary Breast Ovarian Cancer Clinic Sung-Won Kim, MD, PhD, FACS Overview of HBOC
More informationMolecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report of Four Novel Mutations
Korean J Lab Med 2010;30:190-4 DOI 10.3343/kjlm.2010.30.2.190 Original Article Diagnostic Genetics Molecular Characterization of the NF2 Gene in Korean Patients with Neurofibromatosis Type 2: A Report
More informationSALSA MLPA KIT P060-B2 SMA
SALSA MLPA KIT P6-B2 SMA Lot 111, 511: As compared to the previous version B1 (lot 11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). Please note that, in contrast to the
More informationIntroduction to Genetics
Introduction to Genetics Table of contents Chromosome DNA Protein synthesis Mutation Genetic disorder Relationship between genes and cancer Genetic testing Technical concern 2 All living organisms consist
More informationSALSA MLPA KIT P050-B2 CAH
SALSA MLPA KIT P050-B2 CAH Lot 0510, 0909, 0408: Compared to lot 0107, extra control fragments have been added at 88, 96, 100 and 105 nt. The 274 nt probe gives a higher signal in lot 0510 compared to
More informationGenetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain
Genetic Testing For Ovarian Cancer: When, How And Who? Judith Balmaña, MD, PhD University Hospital Vall d Hebron Barcelona, Spain Why Would We Consider Genetic Testing in Patients With Ovarian Cancer?
More informationGenetic Testing: who, what, why?
Genetic Testing: who, what, why? Gina Westhoff MD LMG Gynecologic Oncology March 16, 2019 Disclosures Speaker for Merck (unrelated to today s topic) Objectives Determine who should undergo genetic risk
More informationSupplemental Data: Detailed Characteristics of Patients with MKRN3. Patient 1 was born after an uneventful pregnancy. She presented in our
1 2 Supplemental Data: Detailed Characteristics of Patients with MKRN3 Mutations 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 Patient 1 was born after an uneventful pregnancy. She presented
More informationHereditary Prostate Cancer: From Gene Discovery to Clinical Implementation
Hereditary Prostate Cancer: From Gene Discovery to Clinical Implementation Kathleen A. Cooney, MD MACP Duke University School of Medicine Duke Cancer Institute (No disclosures to report) Overview Prostate
More informationThe lymphoma-associated NPM-ALK oncogene elicits a p16ink4a/prb-dependent tumor-suppressive pathway. Blood Jun 16;117(24):
DNA Sequencing Publications Standard Sequencing 1 Carro MS et al. DEK Expression is controlled by E2F and deregulated in diverse tumor types. Cell Cycle. 2006 Jun;5(11) 2 Lassandro L et al. The DNA sequence
More informationMRC-Holland MLPA. Description version 06; 23 December 2016
SALSA MLPA probemix P417-B2 BAP1 Lot B2-1216. As compared to version B1 (lot B1-0215), two reference probes have been added and two target probes have a minor change in length. The BAP1 (BRCA1 associated
More informationGenome 371, Autumn 2018 Quiz Section 9: Genetics of Cancer Worksheet
Genome 371, Autumn 2018 Quiz Section 9: Genetics of Cancer Worksheet All cancer is due to genetic mutations. However, in cancer that clusters in families (familial cancer) at least one of these mutations
More informationMEDICAL GENOMICS LABORATORY. Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG)
Next-Gen Sequencing and Deletion/Duplication Analysis of NF1 Only (NF1-NG) Ordering Information Acceptable specimen types: Fresh blood sample (3-6 ml EDTA; no time limitations associated with receipt)
More informationSupplementary information. Supplementary figure 1. Flow chart of study design
Supplementary information Supplementary figure 1. Flow chart of study design Supplementary Figure 2. Quantile-quantile plot of stage 1 results QQ plot of the observed -log10 P-values (y axis) versus the
More informationTumor suppressor genes D R. S H O S S E I N I - A S L
Tumor suppressor genes 1 D R. S H O S S E I N I - A S L What is a Tumor Suppressor Gene? 2 A tumor suppressor gene is a type of cancer gene that is created by loss-of function mutations. In contrast to
More informationPrevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D.
Prevalence and clinical implications of BRCA1/2 germline mutations in Chinese women with breast cancer Yuntao Xie M.D., Ph.D. Hereditary Cancer Center, Peking University Cancer Hospital 1 Breast cancer
More informationRicombinazione omologa nel carcinoma ovarico: BRCA e oltre. F. Raspagliesi MD
Ricombinazione omologa nel carcinoma ovarico: BRCA e oltre F. Raspagliesi MD raspagliesi@istitutotumori.mi.it BRCA molecular signature in ovarian cancer In a pooled analysis of 26 observational studies
More informationCPT Codes for Pharmacogenomic Tests
CPT s for Pharmacogenomic Tests The table below lists CPT codes and lab fee information for pharmacogenomic tests as established by the Centers for Medicare and Medicaid Services. It was compiled by the
More informationNGS for Cancer Predisposition
NGS for Cancer Predisposition Colin Pritchard MD, PhD University of Washington Dept. of Lab Medicine AMP Companion Society Meeting USCAP Boston March 22, 2015 Disclosures I am an employee of the University
More informationTumorNext-HRD with OvaNext: Paired Germline and Tumor Analyses of Genes Involved in
SAMPLE REPORT Ordered By Contact ID:1251298 Example, Doctor, MD MOCKORG44 (10829) 123 Somewhere LaneSuite 4 Heaven NV 78872 US Ph:123-123-1234 Fx:123-123-1223 Org ID:8141 Normal Specimen Accession #: 00-086947
More informationLESSON 3.2 WORKBOOK. How do normal cells become cancer cells? Workbook Lesson 3.2
For a complete list of defined terms, see the Glossary. Transformation the process by which a cell acquires characteristics of a tumor cell. LESSON 3.2 WORKBOOK How do normal cells become cancer cells?
More informationNon-Mendelian inheritance
Non-Mendelian inheritance Focus on Human Disorders Peter K. Rogan, Ph.D. Laboratory of Human Molecular Genetics Children s Mercy Hospital Schools of Medicine & Computer Science and Engineering University
More informationProduct Description SALSA MLPA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol.
Product Description SALSA Probemix P002-D1 BRCA1 To be used with the MLPA General Protocol. Version D1. For a complete product history see page 11. Catalogue numbers: P002-025R: SALSA MLPA probemix P002
More informationStatistical Analysis of Single Nucleotide Polymorphism Microarrays in Cancer Studies
Statistical Analysis of Single Nucleotide Polymorphism Microarrays in Cancer Studies Stanford Biostatistics Workshop Pierre Neuvial with Henrik Bengtsson and Terry Speed Department of Statistics, UC Berkeley
More informationMRC-Holland MLPA. Description version 30; 06 June 2017
SALSA MLPA probemix P081-C1/P082-C1 NF1 P081 Lot C1-0517, C1-0114. As compared to the previous B2 version (lot B2-0813, B2-0912), 11 target probes are replaced or added, and 10 new reference probes are
More informationCharacterisation of structural variation in breast. cancer genomes using paired-end sequencing on. the Illumina Genome Analyser
Characterisation of structural variation in breast cancer genomes using paired-end sequencing on the Illumina Genome Analyser Phil Stephens Cancer Genome Project Why is it important to study cancer? Why
More informationNext Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters
Next Generation Sequencing as a tool for breakpoint analysis in rearrangements of the globin-gene clusters XXXth International Symposium on Technical Innovations in Laboratory Hematology Honolulu, Hawaii
More informationMRC-Holland MLPA. Description version 19;
SALSA MLPA probemix P6-B2 SMA Lot B2-712, B2-312, B2-111, B2-511: As compared to the previous version B1 (lot B1-11), the 88 and 96 nt DNA Denaturation control fragments have been replaced (QDX2). SPINAL
More informationGENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2
GENETIC TESTING FOR HEREDITARY BREAST AND OVARIAN CANCER BRCA1 BRCA2 Coverage for services, procedures, medical devices and drugs are dependent upon benefit eligibility as outlined in the member's specific
More informationOutline. Identifying your risk for hereditary breast or ovarian cancer. Genetics 101. What causes cancer? Genetics
Identifying your risk for hereditary breast or ovarian cancer David Andorsky, MD Breanna Roscow, MS, CGC 303-993-0161 Outline Genetics and biology of hereditary cancer syndromes BRCA1 and BRCA2 Genetic
More informationReference #: SYS-PC-VPCI-CG-002. Origination Date: June 2012 Next Review Date: April 2019 Effective Date: April 2016
Oncology Service Line-Allina Health System-wide Consensus Guidelines: Identification of Breast Cancer Patients at Risk for Inherited Cancer Risks These guidelines apply to clinical interventions that have
More informationIntroduction to LOH and Allele Specific Copy Number User Forum
Introduction to LOH and Allele Specific Copy Number User Forum Jonathan Gerstenhaber Introduction to LOH and ASCN User Forum Contents 1. Loss of heterozygosity Analysis procedure Types of baselines 2.
More informationManaging Moderate Penetrance
Managing Moderate Penetrance Thomas Slavin, MD, FACMG Assistant Clinical Professor, Department of Medical Oncology, Division of Clinical Cancer Genetics Program Member, Cancer Control and Population Sciences
More informationUse of panel tests in place of single gene tests in the cancer genetics clinic
Clin Genet 2015: 88: 278 282 Printed in Singapore. All rights reserved CLINICAL GENETICS doi: 10.1111/cge.12488 Short Report se of panel tests in place of single gene tests in the cancer genetics clinic
More informationPerformance Characteristics BRCA MASTR Plus Dx
Performance Characteristics BRCA MASTR Plus Dx with drmid Dx for Illumina NGS systems Manufacturer Multiplicom N.V. Galileïlaan 18 2845 Niel Belgium Table of Contents 1. Workflow... 4 2. Performance Characteristics
More informationGENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER. Dr Abhijit Dixit. Family Health Clinical Genetics
GENETIC MANAGEMENT OF A FAMILY HISTORY OF BREAST AND / OR OVARIAN CANCER Full Title of Guideline: Author (include email and role): Division & Speciality: Scope (Target audience, state if Trust wide): Review
More informationRole of Genetic Counseling Nurse in Breast Cancer. Sung-Won Kim, MD, PhD, FACS CEO & President Daerim St. Mary s Hospital
Role of Genetic Counseling Nurse in Breast Cancer Sung-Won Kim, MD, PhD, FACS CEO & President Daerim St. Mary s Hospital What is hereditary breast cancer? Hereditary (5-10%): Mutated phenotype of a specific
More informationCASE REPORT A family study of HbS in a Malay family by molecular analysis
Malaysian J Pathol 2010; 32(2) : 137 141 CASE REPORT A family study of HbS in a Malay family by molecular analysis HAFIZA Alauddin MBBS, MPath, NOOR HAMIDAH Hussin MBBCh, MD, NOOR FARISAH A Razak BSc,
More informationHereditary Breast and Ovarian Cancer Rebecca Sutphen, MD, FACMG
Hereditary Breast and Ovarian Cancer 2015 Rebecca Sutphen, MD, FACMG Among a consecutive series of 11,159 women requesting BRCA testing over one year, 3874 responded to a mailed survey. Most respondents
More informationGenomic structural variation
Genomic structural variation Mario Cáceres The new genomic variation DNA sequence differs across individuals much more than researchers had suspected through structural changes A huge amount of structural
More informationMutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research
Mutation Detection and CNV Analysis for Illumina Sequencing data from HaloPlex Target Enrichment Panels using NextGENe Software for Clinical Research Application Note Authors John McGuigan, Megan Manion,
More informationCorporate Medical Policy Genetic Testing for Breast and Ovarian Cancer
Corporate Medical Policy Genetic Testing for Breast and Ovarian Cancer File Name: Origination: Last CAP Review: Next CAP Review: Last Review: genetic_testing_for_breast_and_ovarian_cancer 8/1997 8/2017
More informationSALSA MLPA probemix P315-B1 EGFR
SALSA MLPA probemix P315-B1 EGFR Lot B1-0215 and B1-0112. As compared to the previous A1 version (lot 0208), two mutation-specific probes for the EGFR mutations L858R and T709M as well as one additional
More informationThe Next Generation of Hereditary Cancer Testing
The Next Generation of Hereditary Cancer Testing Why Genetic Testing? Cancers can appear to run in families. Often this is due to shared environmental or lifestyle patterns, such as tobacco use. However,
More informationDNA-seq Bioinformatics Analysis: Copy Number Variation
DNA-seq Bioinformatics Analysis: Copy Number Variation Elodie Girard elodie.girard@curie.fr U900 institut Curie, INSERM, Mines ParisTech, PSL Research University Paris, France NGS Applications 5C HiC DNA-seq
More informationIdentification of regions with common copy-number variations using SNP array
Identification of regions with common copy-number variations using SNP array Agus Salim Epidemiology and Public Health National University of Singapore Copy Number Variation (CNV) Copy number alteration
More informationCASE STUDY. Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk. Introduction.
CASE STUDY Germline Test for Mother and Follow up Testing for Daughter: Assessment of Hereditary Cancer Risk Introduction Germline cancer risk assessment tests are well-prescribed tests from Strand Life
More informationThe burden of prostate cancer in Asia: prevalence & screening
Asia Pasific Prostate Society (APPS) March 04, 2011 Seoul The burden of prostate cancer in Asia: prevalence & screening Yasutomo Nasu Okayama University Okayama Japan Asia Pasific Prostate Society (APPS)
More informationMultigene Panel Testing for Hereditary Cancer Risk
Multigene Panel Testing for Hereditary Cancer Risk Dana Zakalik, M.D. Director, Nancy and James Grosfeld Cancer Genetics Center Professor, OUWB Medical School MCC Annual Meeting November 4, 2015 Outline
More informationContribution of BRCA1 large genomic rearrangements to earlyonset and familial breast/ovarian cancer in Pakistan
DOI 10.1007/s10549-016-4044-0 PRECLINICAL STUDY Contribution of BRCA1 large genomic rearrangements to earlyonset and familial breast/ovarian cancer in Pakistan Muhammad U. Rashid 1,2 Noor Muhammad 1 Asim
More informationGEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T. Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics
GEN ETICS AN D GEN OM ICS IN CANCER PREVENTION AN D TREATM EN T Robert Nathan Slotnick MD PhD Director, Medical Genetics and Genomics The Medical/Surgical/Radiation Oncologist s View of Genetics Cancer
More informationHands-On Ten The BRCA1 Gene and Protein
Hands-On Ten The BRCA1 Gene and Protein Objective: To review transcription, translation, reading frames, mutations, and reading files from GenBank, and to review some of the bioinformatics tools, such
More informationAccel-Amplicon Panels
Accel-Amplicon Panels Amplicon sequencing has emerged as a reliable, cost-effective method for ultra-deep targeted sequencing. This highly adaptable approach is especially applicable for in-depth interrogation
More informationPolicy Specific Section: Medical Necessity and Investigational / Experimental. October 15, 1997 October 9, 2013
Medical Policy Genetic Testing for Hereditary Breast and/or Ovarian Cancer Type: Medical Necessity and Investigational / Experimental Policy Specific Section: Laboratory/Pathology Original Policy Date:
More informationModerate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk
Moderate Penetrance Variants Associated With Breast Cancer in Individuals at High Breast Cancer Risk Policy Number: 2.04.126 Last Review: 3/2018 Origination: 3/2017 Next Review: 3/2019 Policy Blue Cross
More informationAbstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50
Abstract # 1503: Predisposing germline mutations in high grade ER+ HER2- breast cancer patients diagnosed age < 50 Garber JE 1, Tung NM 2, Elkin EP 3, Allen BA 3, Singh NA 3, Wenstrup R 3, Hartman AR 3,
More informationUNIVERSITI TEKNOLOGI MARA COPY NUMBER VARIATIONS OF ORANG ASLI (NEGRITO) FROM PENINSULAR MALAYSIA
UNIVERSITI TEKNOLOGI MARA COPY NUMBER VARIATIONS OF ORANG ASLI (NEGRITO) FROM PENINSULAR MALAYSIA SITI SHUHADA MOKHTAR Thesis submitted in fulfillment of the requirements for the degree of Master of Science
More informationAssociation-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis
Supplementary Material Association-heterogeneity mapping identifies an Asian-specific association of the GTF2I locus with rheumatoid arthritis Kwangwoo Kim 1,, So-Young Bang 1,, Katsunori Ikari 2,3, Dae
More informationHereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with
Hereditary breast cancer who to refer to a cancer genetics clinic and how to counsel patients with positive and negative results? SAMO Workshop Luzern 3./4.10.2014 Dr. med. Barbara Bolliger TumorTumor-
More informationGenetic Testing for BRCA1 and BRCA2 Genes
Genetic Testing for BRCA1 and BRCA2 Genes MP9478 Covered Service: Prior Authorization Required: Additional Information: Yes when meets criteria below Yes as shown below Pre and post-test genetic counseling
More informationMRC-Holland MLPA. Description version 07; 26 November 2015
SALSA MLPA probemix P266-B1 CLCNKB Lot B1-0415, B1-0911. As compared to version A1 (lot A1-0908), one target probe for CLCNKB (exon 11) has been replaced. In addition, one reference probe has been replaced
More informationMEDICAL GENOMICS LABORATORY. Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG)
Peripheral Nerve Sheath Tumor Panel by Next-Gen Sequencing (PNT-NG) Ordering Information Acceptable specimen types: Blood (3-6ml EDTA; no time limitations associated with receipt) Saliva (OGR-575 DNA Genotek;
More information1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45
1 2 3 1. Collaborative Group on Epidemiological Studies of Ovarian Cancer. Ovarian cancer and oral contraceptives: collaborative reanalysis of data from 45 epidemiological studies including 23,257 women
More informationNovember 9, Johns Hopkins School of Medicine, Baltimore, MD,
Fast detection of de-novo copy number variants from case-parent SNP arrays identifies a deletion on chromosome 7p14.1 associated with non-syndromic isolated cleft lip/palate Samuel G. Younkin 1, Robert
More information# For the GWAS stage, B-cell NHL cases which small numbers (N<20) were excluded from analysis.
Supplementary Table 1a. Subtype Breakdown of all analyzed samples Stage GWAS Singapore Validation 1 Guangzhou Validation 2 Guangzhou Validation 3 Beijing Total No. of B-Cell Cases 253 # 168^ 294^ 713^
More information6/8/17. Genetics 101. Professor, College of Medicine. President & Chief Medical Officer. Hereditary Breast and Ovarian Cancer 2017
Genetics 101 Hereditary Breast and Ovarian Cancer 2017 Rebecca Sutphen, MD, FACMG Professor, College of Medicine President & Chief Medical Officer INVASIVE CANCER GENETICALLY ALTERED CELL HYPERPLASIA DYSPLASIA
More informationEuropean Journal of Medical Research. Open Access RESEARCH. Weiming Hao 1,2, Xia Xu 3, Haifeng Shi 1, Chiyu Zhang 2 and Xiaoxiang Chen 4*
https://doi.org/10.1186/s40001-018-0345-6 European Journal of Medical Research RESEARCH Open Access No association of TP53 codon 72 and intron 3 16 bp duplication polymorphisms with breast cancer risk
More informationUniversity of Groningen
University of Groningen Prevalence of and BRCA2 Germline Mutations in Breast Cancer Women of Multiple Ethnic Region in Northwest China Ou, Jianghua; Wu, Tao; Sijmons, Roelof; Ni, Duo; Xu, Wenting; Upur,
More informationCHEK2 1100delC and Del5395bp mutations in BRCAnegative individuals from Serbian hereditary breast and ovarian cancer families
JBUON 2013; 18(3): 594-600 ISSN: 1107-0625, online ISSN: 2241-6293 www.jbuon.com E-mail: editorial_office@jbuon.com ORIGINAL ARTICLE CHEK2 1100delC and Del5395bp mutations in BRCAnegative individuals from
More informationDoes Cancer Run in Your Family?
Does Cancer Run in Your Family? Nancie Petrucelli, MS, CGC Clinical Assistant Professor Certified Genetic Counselor/Coordinator Cancer Genetic Counseling Service Karmanos Cancer Institute Wayne State University
More information